



EUROPEAN COMMISSION

HEALTH & CONSUMERS DIRECTORATE-GENERAL

D(2009) 411535

## **SUMMARY REPORT OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH**

Section *PLANT PROTECTION PRODUCTS - LEGISLATION*

**2 October 2009**

President: M. Flüh

*26 Member States were present. Cyprus was absent and represented by Greece.*

*Qualified majority: 255 votes and 14 Member States in favour.*

- 1. Examination and possible opinion on a draft Commission Decision correcting Directive 2003/23/EC amending Council Directive 91/414/EEC to include imazamox, oxasulfuron, ethoxysulfuron, foramsulfuron, oxadiargyl and cyazofamid as active substance (SANCO/5856/2009 Rev. 3) (RR SANCO/14323/2000 final)**

The Committee took note of the review report outlined in document SANCO/14323/2000 final.

*Vote: Unanimous favourable opinion.*

- 2. Examination and possible opinion on a draft Commission Directive concerning the inclusion of cyflufenamid in Annex I to Directive 91/414/EEC (SANCO/6138/2009 Rev. 2) (DRR SANCO/6612/2009 Rev. 1)**

The Committee took note of the review report outlined in document SANCO/6612/2009 Rev. 1.

*Vote: Favourable opinion by qualified majority (14 votes against, 25 MS in favour).*

- 3. Examination and possible opinion on a draft Commission Directive amending Annex I to Council Directive 91/414/EEC as regards the common name and the purity of the active substance hydrolysed proteins (SANCO/6615/2009)(RR SANCO/2615/2008 Rev. 3)**

The Committee took note of the review report outlined in document SANCO/2615/2008 Rev. 3.

*Vote: Unanimous favourable opinion.*

4. **Examination and possible opinion on a draft Commission Directive amending Council Directive 91/414/EEC as regards the expiry date for inclusion in Annex I of the active substance carbendazim (SANCO/6426/2009 Rev. 1)**

*Vote: Favourable opinion by qualified majority (43 votes against, 24 MS in favour).*

5. **Examination and possible opinion on a draft Commission Directive correcting Directive 2008/125/EC amending Council Directive 91/414/EEC to include aluminium phosphide, calcium phosphide, magnesium phosphide, cymoxanil, dodemorph, 2,5-dichlorobenzoic acid methylester, metamitron, sulcotrione, tebuconazole and triadimenol as active substances (SANCO/6383/2009 Rev. 1)**

*Vote: Favourable opinion by qualified majority (29 abstentions, 10 votes against, 25 MS in favour).*

6. **Examination and possible opinion on a draft Commission proposal and review report on cadusafos (SANCO/6640/2009)**

*Vote postponed.*

7. **Examination and possible opinion on a draft Commission Decision extending provisional authorisations for metaflumizone and gamma-cyhalothrin (SANCO/6883/2009 Rev. 1)**

*Vote: Unanimous favourable opinion.*

8. **New strain of *Cydia pomonella* GV authorised in NL – amended review report SANCO/1548/08 Rev. 4**

The Committee took note of the review report outlined in document SANCO/1548/08 Rev. 4.

9. **Notifications under Article 8(4) of the Directive 91/414/EEC**

The following notifications have been received:

1,3-D (BE)

1,3-D (EL)

1,3-D (MT)

8-Hydroxychinolin (DE)

Boscalid (CZ)

Carfentrazone-ethyl (DK)

Dimethomorph-Mancozeb (AT)

Fenoxycarb (SK)

Formaldehyde (NL)

Imazamox (BG)

Lambda-cyhalothrin (NL)

Lambda-cyhalotrin (PL)

Linuron (DE)

Linuron (UK)

Maleic hydrazide (DE)

Methiocarb (LT)

Pyraclostrobin, boscalid (NL)

Pyraclostrobin, boscalid (SK)

Spinosad (CZ)

Streptomycin (SK)

Tebuconazole (BG)

Tebuconazole (BG)

Thiachloprid (PL)

Thiametoxam, metalaxyl-M, fludioxinil(BG)

The Committee took note of the notifications submitted by AT, BE, BG, CY, CZ, DE, DK, EL, MT, NL, SK, UK.

The Commission recalls that under the provisions of article 8(4) of Directive 91/414/EEC Member States are obliged to inform the Commission and the other Member States immediately after they granted such derogation.

As regards streptomycin, the Commission recalled that uses of antibiotics in general must be minimised in order to avoid antimicrobial resistance. Their agricultural application has been phased out and any uses under Article 8(4) should be exceptional. Quantities actually used or resistance observed are to be reported to the Commission.

In addition, the Commission pointed out that if a maximum residue level (MRL) set under Reg. (EC) No 396/2005 cannot be met and a national MRL is set, a consumer risk assessment has to be carried out and forwarded to the Commission, EFSA and Member States.

Member States are reminded that they shall put in place the necessary risk mitigation measures to ensure acceptable uses for human and animal health and the environment.

**10. Guidance document on the procedures for submission and assessment of confirmatory data following inclusion of an active substance in Annex I of Council Directive 91/414/EEC. (SANCO/5634/2009 Rev. 3)**

The Committee took note of the guideline set out in document SANCO/5634/2009 Rev. 3.

**11. Guidance document on the presentation and evaluation of dossiers according to annex III of Directive 91/414/EEC in the format of a (draft) Registration Report (SANCO/6895/2009 Rev. 1)**

The Committee took note of the guideline set out in document SANCO/6895/2009 Rev. 1.

**12. Guidance document on a process for intra & inter-zonal work-sharing to facilitate the registration and re-registration of plant protection products following inclusion of an active substance in Annex I of Council Directive 91/414/EEC (SANCO/6896/2009 Rev. 1)**

The Committee took note of the guideline set out in document SANCO/6896/2009 Rev. 1.

**13. Guidance document on the procedures relating to the authorisation of plant protection products following inclusion of an existing active substance in Annex I Council Directive 91/414/EEC (SANCO/10796/2003 Rev. 10.4)**

The Committee took note of the guideline set out in document SANCO/10796/2003 Rev. 10.4.

**14. Amended final review report of quizalofop-p (SANCO/169/2008 rev. 02.10.2009).**

The Committee took note of the review report outlined in document SANCO/169/2008 Rev. 02.10.2009.

**15. Any other business:**

*01. Resubmissions -respect of deadlines for additional report.*

*The Commission reminds Member States to submit in time (at the latest within 6 months) the additional assessment report for re-submitted active substance. This is essential to ensure that decision making can be finalised in time.*

*02. Submission of draft assessment report for Renewal of Annex I inclusion*

*The commission informs Member States that it is considering taking legal action against those Member States who did not submit in time their assessment report (as foreseen in Article 10 of Commission Regulation (EC) No 737/2007).*